)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Orchid Pharma (ORCHPHARMA) investor relations material
Orchid Pharma Q1 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 25/26 earnings summary12 Aug, 2025
Executive summary
Q1 FY26 sales declined 29% year-over-year to ₹173 crore amid a global antibiotics market slowdown, with EBITDA and PAT also dropping sharply compared to Q1 FY25.
Board approved unaudited standalone and consolidated financial results for Q1 FY26, with statutory auditors expressing an unmodified opinion on standalone and a modified opinion on consolidated results.
Strategic acquisition of global rights to enmetazobactam and Exblifep from Allecra, positioning the company as an innovator of a new chemical entity.
All future economic benefits and royalties from the acquired product will accrue directly to the company.
Appointments of internal, cost, and secretarial auditors for FY2025-26 and beyond were approved, subject to member ratification.
Financial highlights
Q1 FY26 sales: ₹173 crore, down from ₹244 crore in Q1 FY25; standalone total income for Q1 FY26 was ₹18,885.92 lakhs.
Q1 FY26 EBITDA: ₹14 crore; standalone net profit: ₹1,819.74 lakhs; consolidated net profit: ₹1,475.58 lakhs.
Q1 FY26 PAT declined 38% to ₹18 crore; basic and diluted EPS (standalone) for Q1 FY26 stood at ₹3.59.
Q1 FY26 EBITDA margin was 9.6% (standalone), and 17% (consolidated); gross margin was 42%.
Other income doubled in Q1 FY26 to ₹16 crore year-over-year.
Outlook and guidance
No near-term revival expected in the antibiotics market; persistent volume and price pressures anticipated for the rest of the year.
Focus remains on margin discipline, selective investment in growth, and global expansion of Exblifep licensing.
Board and management continue to focus on operational efficiency and capital deployment, with ongoing investments in manufacturing and API facility expansion.
US out-licensing deal for enmetazobactam targeted within one year of acquisition completion.
FY-25 full-year results indicate positive momentum with double-digit growth in sales and profitability compared to FY-24.
Exblifep US market entry challenges and plan?
Cefiderocol's strategy against Zidebactam?
Antibiotics market share vs. margin strategy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Orchid Pharma earnings date
Q2 25/2610 Nov, 2025
Next Orchid Pharma earnings date
Q2 25/2610 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Orchid Pharma Limited is a pharmaceutical company engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs) and finished dosage formulations. The company focuses on therapeutic areas such as anti-infectives, including beta-lactam antibiotics, and also operates in segments like cardiovascular and central nervous system treatments. Its operations include research and development, chemical synthesis, and formulation development for both domestic and international markets. The company is headquartered in Chennai, India, and its shares are listed on the BSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage